41.
Condorelli F, Genazzani AA. Dasatinib: Is it All in the Dose?
BioDrugs. 2010 Mar 22. doi: 10.2165/11535870-000000000-00000.
40.
Colombano G, Travelli C, Galli U, Caldarelli A, Chini MG, Canonico PL, Sorba G, Bifulco G, Tron GC, Genazzani AA.
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
J Med Chem. 2010 Jan 28;53(2):616-23.
39.
Pirali T, Faccio V, Mossetti R, Grolla AA, Di Micco S, Bifulco G, Genazzani AA, Tron GC.
Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide
mimetics by a tandem three-component reaction and intramolecular [3+2] cycloaddition. Mol Divers.
2010 Feb;14(1):109-21.
38.
Terrazzino S, Viana M, Floriddia E, Monaco F, Mittino D, Sances G, Tassorelli C, Nappi G, Rinaldi M, Canonico PL, Genazzani AA.
The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients.
Eur J Pharm 2010, in press.
37.
Terrazzino S, Sances G, Balsamo F, Viana M, Monaco F, Bellomo G, Martignoni E, Tassorelli C,
Nappi G, Canonico PL, Genazzani AA.
Role of two common variants of 5HT2A gene in medication overuse headache.
Headache 2010, in press.
36.
Grolla AA, Podestà V, Chini MG, Di Micco S, Vallario A,
Genazzani AA, Canonico PL, Bifulco G, Tron GC, Sorba G, Pirali
T. Synthesis, biological evaluation, and molecular docking of Ugi
products containing a zinc-chelating moiety as novel inhibitors of
histone deacetylases. J Med Chem. 2009 May 14;52(9):2776-85
